

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bain Capital Life Sciences Investors, LLC</u> <hr/> (Last) (First) (Middle) 200 CLARENDON STREET <hr/> (Street) BOSTON MA 02116 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/23/2020	3. Issuer Name and Ticker or Trading Symbol <u>Annexon, Inc. [ ANNX ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series C Preferred Stock	(1)	(1)	Common Stock	22,222,221 <sup>(1)</sup>	(1)	I	See Footnotes <sup>(3)(5)(6)</sup>
Series D Preferred Stock	(2)	(2)	Common Stock	2,812,543 <sup>(2)</sup>	(2)	I	See Footnotes <sup>(4)(5)(6)</sup>

1. Name and Address of Reporting Person* <u>Bain Capital Life Sciences Investors, LLC</u> <hr/> (Last) (First) (Middle) 200 CLARENDON STREET <hr/> (Street) BOSTON MA 02116 <hr/> (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>Bain Capital Life Sciences Partners, LP</u> <hr/> (Last) (First) (Middle) 200 CLARENDON STREET <hr/> (Street) BOSTON MA 02116 <hr/> (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>Bain Capital Life Sciences Fund, L.P.</u>
--

(Last) (First) (Middle)

200 CLARENDON STREET

(Street)

BOSTON MA 02116

(City)

(State)

(Zip)

1. Name and Address of Reporting Person\*

[BCIP Life Sciences Associates, LP](#)

(Last) (First) (Middle)

200 CLARENDON STREET

(Street)

BOSTON MA 02116

(City)

(State)

(Zip)

1. Name and Address of Reporting Person\*

[Koppel Adam](#)

(Last) (First) (Middle)

C/O BAIN CAPITAL LIFE SCIENCES  
INVESTORS  
LLC, 200 CLARENDON STREET

(Street)

BOSTON MA 02116

(City)

(State)

(Zip)

1. Name and Address of Reporting Person\*

[Schwartz Jeffrey Lawrence](#)

(Last) (First) (Middle)

C/O BAIN CAPITAL LIFE SCIENCES  
INVESTORS  
LLC, 200 CLARENDON STREET

(Street)

BOSTON MA 02116

(City)

(State)

(Zip)

**Explanation of Responses:**

1. The shares of Series C Preferred Stock will automatically convert on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
2. The shares of Series D Preferred Stock will automatically convert on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
3. Represents 20,158,775 shares of Series C Preferred Stock held of record by Bain Capital Life Sciences Fund, L.P. ("BCLS") and 2,063,446 shares of Series C Preferred Stock held of record by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").
4. Represents 2,551,384 shares of Series D Preferred Stock held of record by BCLS and 261,159 shares of Series D Preferred Stock held of record by BCIPLS.
5. Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein.
6. Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

**Remarks:**

[BAIN CAPITAL LIFE  
SCIENCES INVESTORS,  
LLC, By: /s/ Jeffrey  
Schwartz, Name: Jeffrey  
Schwartz, Title: Managing  
Director](#) 07/23/2020

BAIN CAPITAL LIFE 07/23/2020

SCIENCES PARTNERS,  
LP, By: Bain Capital Life  
Sciences Investors, LLC,  
its general partner, By: /s/  
Jeffrey Schwartz, Name:  
Jeffrey Schwartz, Title:  
Managing Director

BAIN CAPITAL LIFE  
SCIENCES FUND, L.P.,

By: Bain Capital Life  
Sciences Partners, LP, its  
general partner, By: Bain  
Capital Life Sciences

07/23/2020

Investors, LLC, its general  
partner, By: /s/ Jeffrey  
Schwartz, Name: Jeffrey  
Schwartz, Title: Managing  
Director

BCIP LIFE SCIENCES  
ASSOCIATES, LP, By:

Boylston Coinvestors,  
LLC, its general partner,

By: /s/ Jeffrey Schwartz,  
Name: Jeffrey Schwartz,

Title: Authorized  
Signatory.

07/23/2020

/s/ Adam Koppel

07/23/2020

/s/ Jeffrey Schwartz

07/23/2020

\*\* Signature of Reporting  
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**